NIH-funded study discovers new genes for childhood epilepsies
New strategy may find more genes and provide a better understanding of these and other complex neurological disorders
A genetic study of childhood epilepsies has linked two new genes to severe forms of disease and provides a novel strategy for identifying therapy targets. This study used a cutting-edge genetic technique, called exome sequencing, to search for new mutations that are not inherited. The results suggest this may be a highly effective way to find and confirm many disease-causing gene mutations.
“It appears that the time for using this approach to understand complex neurological disorders has arrived,” said David Goldstein, Ph.D., director of the Center for Human Genome Variation at Duke University Medical Center, Durham, N.C., and a leader of the study. “This moderately-sized study identified an unusually large number of disease-causing mutations and provides a wealth of new information for the epilepsy research community to explore.”
The study is part of a worldwide, $25 million project, largely funded by the National Institutes of Health, called Epilepsy 4000 (Epi4K ). Epi4K’s mission is to use the latest genetic techniques to sequence and analyze DNA from 4000 epilepsy patients and their relatives. To do this, the researchers and NIH staff involved organized a team of international research institutions devoted to the mission, called the Epilepsy Centers without Walls. This approach facilitates the sharing and analysis of DNA sequences and patient information among the dozens of institutions participating in the project. The study, published in Nature by the Epi4K and Epilepsy Phenome/Genome Project (EPGP) Investigators, found as many as 25 epilepsy-causing mutations in new and previously identified genes.
“These promising results highlight the strength of supporting large international research teams devoted to studying the genetics behind highly complex neurological disorders,” said Story Landis, Ph.D., director of NIH’s National Institute of Neurological Disorders and Stroke (NINDS). The project is also led by Daniel Lowenstein, M.D., a vice chair of the Department of Neurology at the University of California, San Francisco (UCSF) and Sam Berkovic, M.D., director of the Epilepsy Research Center at the University of Melbourne, Australia on behalf of an international team of investigators.
Epilepsy is a group of neurological disorders caused by abnormal firing of nerve cells in the brain which often produces debilitating seizures and a range of other symptoms. More than 2 million people in the United States suffer from epilepsies, and infants and children have a greater chance of having the disorders than adults. Although some studies have found genes associated with rare inherited forms of epilepsy, finding genes associated with the majority of epilepsies has been difficult.
“Unlike some diseases many of the genetic mutations associated with severe childhood epilepsies appear to be new mutations that are not inherited,” said Randall Stewart, Ph.D., a program director at NINDS. “This Epi4K-EPGP project was established to find such mutations.”
In this study, the researchers used exome sequencing to find mutations that might cause two devastating forms of childhood epilepsy, called infantile spasms and Lennox-Gastaut Syndrome. DNA and clinical data were originally collected through the NIH-funded Epilepsy Phenome/Genome Project which was led by Dr. Lowenstein and Elliot Sherr, M.D., Ph.D., director of the Comprehensive Center for Brain Development at UCSF and Dr. Ruben Kuzneicky, M.D., professor at the New York University Comprehensive Epilepsy Center.
“The Epilepsy Phenome/Genome Project, with its massive data set, laid the groundwork for this study, and the key to this success has been the extraordinary level of collaboration among more than 115 investigators, study coordinators and administrative personnel involved in both EPGP and Epi4K,” said Dr. Lowenstein.
Exomes essentially represent all of a person’s genes. Their DNA sequences provide the instructions for constructing all the proteins made by the body. The researchers compared exome sequences of 264 children with the sequences of their parents who do not have epilepsy. Differences in the sequences of these subject trios were analyzed using a number of statistical tools to identify potential disease causing mutations. Compared with some genetic studies, this research sequenced DNA from relatively few patients. Nonetheless, the researchers were able to find disease-causing mutations in six genes: four had been described before using other genetic techniques and two genes are implicated for the first time.
Using novel genetic analysis techniques, the researchers also demonstrated that epilepsy-causing mutations are concentrated in genes that are highly sensitive, or intolerant, to changes in their DNA sequence in human populations. These genes are so sensitive that even the slightest change can cause the gene not to work, leading to death or severe forms of diseases.
“This study used a very sophisticated bioinformatics approach to analyze DNA sequences and find disease-causing mutations,” said Katrina Gwinn, M.D., a program director at NINDS.
To find more genes that are likely to have epilepsy-causing mutations, the researchers searched thousands of exome sequences from healthy volunteers who participated in the National Heart Lung and Blood Institute Exome Sequencing Project. They looked for gene sequences that had only slight differences among subjects because previous studies showed that these sequences are highly sensitive to mutations. The researchers estimated that up to 90 genes could carry epilepsy-causing mutations and that many of the mutations implicated in the risk of epilepsy have been previously associated with other neurodevelopmental diseases, including autism.
“One of the most encouraging aspects of this study is that we’re beginning to see how best to interpret and make effective use of exome sequence data,” said Dr. Goldstein. “We anticipate that further studies will identify many new disease-causing genes and we intend to develop a watch list of the genes which summarizes their clinical characteristics in way that will be helpful for doctors, patients, and researchers.”
For instance, the researchers analyzed how the genes that could carry epilepsy-causing mutations work and interact. Their analysis showed that the genes can be grouped into a few networks. Each network appears to play an important role in the growth and development of a child’s nervous system.
“It appears that a few pathways may be responsible for many severe pediatric epilepsies,” said Dr. Goldstein, “If true, then understanding epilepsies will be more manageable and we can find common pathways to target with drugs and other therapies.”
In addition to grants from NINDS (NS053998, NS077364, NS077274, NS077303, NS077276), this study was funded by Finding a Cure for Epilepsy and Seizures and the Richard Thalheimer Philanthropic Fund.
For more information about Epilepsy, Infantile Spasms, and Lennox-Gastaut Syndrome, please visit:
NINDS is the nation’s leading funder of research on the brain and nervous system. The NINDS mission is to reduce the burden of neurological disease – a burden borne by every age group, by every segment of society, by people all over the world.
About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
NIH...Turning Discovery Into Health®
EPi4K and EPGP Investigators “De novo mutation in the classic epileptic encephalopathies.” Nature, August 11, 2013. DOI: 10.1038/nature12439